Premium
Compounds in Psoralea corylifolia as human MAOb natural inhibitors (1143.12)
Author(s) -
Zarmouh Najla,
Mazzio Elizabeth,
Soliman Karam
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.1143.12
Subject(s) - psoralea corylifolia , monoamine oxidase b , chemistry , glycyrrhiza uralensis , ic50 , pharmacology , monoamine oxidase , traditional medicine , biochemistry , biology , enzyme , medicine , in vitro , alternative medicine , pathology
Treatment for Parkinson’s disease (PD) involves the use of drugs that address the loss of dopaminergic function by restoring neurotransmitter homeostasis. However, the current drugs can be limiting, in that they do not address disease progression. A renewed interest in monoamine oxidase B inhibitors (MAObIs) for PD as independent therapeutics has emerged after recent clinical trials has shown efficacy of deprenyl and rasagiline monotherapy for early disease management. However, conventional MAOIs have food and drug counter‐interactions and side effects which limit its use. Previously, we screened 905 natural ethanol plant extracts on the enzymatic activity of recombinant human MAOb. In this study, we confirm and determine selectivity of MAOb / MAOa. The data show that extracts of Glycyrrhiza uralensis root have an IC50 of 0.04 mg/ml and a 266 fold MAOb/MAOa specificity; Phellodendron Amurense an IC50 of 0.02 mg/ml and a MAOb/MAOa specificity 45.29 fold; Psoralea Corylifolia (PC) an IC50 of 0.08 mg/ml and a 18.34 fold MAOb/MAOa specificity; Ferula Assa‐Foetida an IC50 of 0.24 mg/ml and a 30.23 fold MAOb/MAOa specificity. Further studies for PC active ingredients revealed that bakuchiol content within the plant may contribute to MAOI. Grant Funding Source : Supported by NIMHD G12 MD007582 and P20 MD006738